Why the study?
Prescribing patterns of antithrombotic therapy in NSTEMI patients differ between 2020 Russian and European clinical practice guidelines and require comparative assessment.
A comparison of 2020 Russian and European guidelines for NSTEMI shows similar anticoagulant recommendations but more complex antiplatelet regimens in the ESC guidelines.
Answers are grounded in this paper and cite their sources.
Differences in antithrombotic patterns versus 2020 guidelines warrant caution; leaves open optimal NSTEMI strategies pending outcome trials.
Highlights. Prescribtion patterns of antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndromes have been comapred in 2020 Russian and European clinical practice guidelines for the management of NSTEMI patients. A comparative assessment of novel approaches of antiplatelet and anticoagulant therapy recommended in 2020 European and Russian clinical practice guidelines for the management of patients with non-ST-segment elevation acute coronary syndrome is reported. In prescribing antiplatelet therapy, ESC guidelines suggest focusing attention on a more complex set of regimens to balance ischemic and hemorrhagic risks. Approaches to prescribing anticoagulant therapy do not differ in the recommendations of two medical societies. Fondaparinux has compelling advantages over other drugs regarding the combination of efficacy and safety in patients.
No takes yet. Share an insight, caveat, or question.
Барбараш et al. (2021) conducted a review in non-ST-segment elevation acute coronary syndromes (NSTEMI). Antithrombotic therapy was evaluated. A comparison of 2020 European and Russian guidelines for NSTEMI reveals similar anticoagulant recommendations, while ESC guidelines suggest more complex antiplatelet regimens.
Synapse has enriched 10 related papers. Consider them for comparative context: